Keyword: Neil Woodford

Biotech IPOs continue to come thick and fast this week, with CAR-T specialist Autolus the latest to list with an impressive $150 million raise.

The round moves the total raised by the company past the $200 million mark and values it at around $2 billion.

CAR-T player Autolus has raised $80 million in a third-round financing that it says will fund proof-of-concept testing for three programs.

In this week's EuroBiotech Report, J&J spins out Idorsia, Bavarian Nordic delays data, Woodford backs dementia fund and more. 

Neil Woodford has invested in the Big Pharma-backed Dementia Discovery Fund.

AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract.

The FDA has knocked back Vernalis’ filing for approval of CCP-07, wiping 12% off the company’s stock price in early trading.

Cell Medica has raised £60 million ($74 million) to expand its clinical pipeline of cancer cellular immunotherapies.

Arix Bioscience has teamed up with Takeda Ventures to create and grow biotechs.